Mayne Builds Oncology Portfolio Through Acquisition Of SuperGen’s Nipent
This article was originally published in The Pink Sheet Daily
Executive Summary
SuperGen said the firms will likely sign additional agreements for other oncology products, including Mitozytrex.
You may also be interested in...
Hospira’s Mayne Event: Acquisition Strengthens Oncology Portfolio
Merger will create the leading generic injectable pharmaceutical company in the world.
Hospira’s Mayne Event: Acquisition Strengthens Oncology Portfolio
Merger will create the leading generic injectable pharmaceutical company in the world.
SuperGen Orathecin Hits Road Block: Phase III Nixed For Combo Claim In Pancreatic Cancer
Phase II trial fails to meet pre-specified threshold for median survival.